rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Mark Anthony McCamish

Director

Company insider

Files Form 4 as: Director, Avadel Pharmaceuticals; Director, Rafael Holdings; Director, Vincera Pharma; President and CEO, Forty Seven; Sr. VP & Chief Medical Officer, Facet Biotech; SVP & Cmo, Pdl Biopharma.

Every Form 4 they filed

In numbers

Trades disclosed
102
Buys
2
Sells
12
Bought
$985K
Sold
$6.3M
Companies
6
Companies where not an officer
3
First trade
21 Feb 2007
Last trade
12 Feb 2026
Last filed
12 Feb 2026

Companies traded

Where they are an officer
Forty SevenDirector, Officer · last 7 Apr 20200 buys · 10 sells
Facet BiotechOfficer · last 2 Apr 20090 buys · 0 sells
Pdl BiopharmaOfficer · last 18 Dec 20080 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Avadel PharmaceuticalsDirector · Biotechnology · last 12 Feb 20262 buys · 2 sells
RFL Rafael HoldingsDirector · Biotechnology · last 5 Jan 20240 buys · 0 sells
Vincera PharmaDirector · last 23 Dec 20200 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 Feb 2026filed 12 Feb 2026Avadel PharmaceuticalsBiotechnologySEC FORM 4 Code D$462K22,000 at $21.00filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—11,000filing
12 Feb 2026filed 12 Feb 2026Avadel PharmaceuticalsBiotechnologySEC FORM 4 Code D$1.4M67,025 at $21.00filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—60,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—60,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—42,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—50,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—42,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—42,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—33,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—11,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—11,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—42,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—42,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—42,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—33,000filing
12 Feb 2026filed 12 Feb 2026Avadel PharmaceuticalsSEC FORM 4 Code D$462K22,000 at $21.00filing
12 Feb 2026filed 12 Feb 2026Avadel PharmaceuticalsSEC FORM 4 Code D$1.4M67,025 at $21.00filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—11,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed14

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.